首页 > 最新文献

Harm Reduction Journal最新文献

英文 中文
Psychosocial factors associated with overdose subsequent to Illicit Drug use: a systematic review and narrative synthesis 与使用非法药物后用药过量相关的社会心理因素:系统综述和叙述性综述
IF 4.4 2区 社会学 Q1 Medicine Pub Date : 2024-04-15 DOI: 10.1186/s12954-024-00999-8
Christopher J. Byrne, Fabio Sani, Donna Thain, Emma H. Fletcher, Amy Malaguti
Psychological and social status, and environmental context, may mediate the likelihood of experiencing overdose subsequent to illicit drug use. The aim of this systematic review was to identify and synthesise psychosocial factors associated with overdose among people who use drugs. This review was registered on Prospero (CRD42021242495). Systematic record searches were undertaken in databases of peer-reviewed literature (Medline, Embase, PsycINFO, and Cinahl) and grey literature sources (Google Scholar) for work published up to and including 14 February 2023. Reference lists of selected full-text papers were searched for additional records. Studies were eligible if they included people who use drugs with a focus on relationships between psychosocial factors and overdose subsequent to illicit drug use. Results were tabulated and narratively synthesised. Twenty-six studies were included in the review, with 150,625 participants: of those 3,383–4072 (3%) experienced overdose. Twenty-one (81%) studies were conducted in North America and 23 (89%) reported polydrug use. Psychosocial factors associated with risk of overdose (n = 103) were identified and thematically organised into ten groups. These were: income; housing instability; incarceration; traumatic experiences; overdose risk perception and past experience; healthcare experiences; perception of own drug use and injecting skills; injecting setting; conditions with physical environment; and social network traits. Global rates of overdose continue to increase, and many guidelines recommend psychosocial interventions for dependent drug use. The factors identified here provide useful targets for practitioners to focus on at the individual level, but many identified will require wider policy changes to affect positive change. Future research should seek to develop and trial interventions targeting factors identified, whilst advocacy for key policy reforms to reduce harm must continue.
心理和社会地位以及环境背景可能会影响吸毒后用药过量的可能性。本系统综述旨在确定和综合与吸毒者用药过量相关的社会心理因素。本综述已在 Prospero 上注册(CRD42021242495)。在同行评审文献数据库(Medline、Embase、PsycINFO 和 Cinahl)和灰色文献来源(Google Scholar)中对 2023 年 2 月 14 日(含)之前发表的文献进行了系统记录检索。对所选全文论文的参考文献列表进行了搜索,以获取更多记录。如果研究对象包括吸毒者,且重点关注社会心理因素与吸毒后用药过量之间的关系,则符合条件。研究结果以表格形式列出,并进行叙述性综合。共有 26 项研究被纳入审查范围,参与人数为 150,625 人:其中 3,383-4072 人(3%)经历过用药过量。21项研究(81%)在北美进行,23项研究(89%)报告了多种药物的使用情况。确定了与用药过量风险相关的社会心理因素(n = 103),并按主题分为十组。这些因素包括:收入;住房不稳定;监禁;创伤经历;对用药过量风险的认识和过去的经历;医疗保健经历;对自身药物使用和注射技能的认识;注射环境;物理环境条件;以及社会网络特征。全球吸毒过量率持续上升,许多指南都建议对依赖性吸毒进行社会心理干预。本文所确定的因素为从业人员提供了在个人层面上重点关注的有用目标,但所确定的许多因素需要更广泛的政策变革才能产生积极的影响。未来的研究应寻求开发和试用针对已确定因素的干预措施,同时必须继续倡导关键的政策改革,以减少伤害。
{"title":"Psychosocial factors associated with overdose subsequent to Illicit Drug use: a systematic review and narrative synthesis","authors":"Christopher J. Byrne, Fabio Sani, Donna Thain, Emma H. Fletcher, Amy Malaguti","doi":"10.1186/s12954-024-00999-8","DOIUrl":"https://doi.org/10.1186/s12954-024-00999-8","url":null,"abstract":"Psychological and social status, and environmental context, may mediate the likelihood of experiencing overdose subsequent to illicit drug use. The aim of this systematic review was to identify and synthesise psychosocial factors associated with overdose among people who use drugs. This review was registered on Prospero (CRD42021242495). Systematic record searches were undertaken in databases of peer-reviewed literature (Medline, Embase, PsycINFO, and Cinahl) and grey literature sources (Google Scholar) for work published up to and including 14 February 2023. Reference lists of selected full-text papers were searched for additional records. Studies were eligible if they included people who use drugs with a focus on relationships between psychosocial factors and overdose subsequent to illicit drug use. Results were tabulated and narratively synthesised. Twenty-six studies were included in the review, with 150,625 participants: of those 3,383–4072 (3%) experienced overdose. Twenty-one (81%) studies were conducted in North America and 23 (89%) reported polydrug use. Psychosocial factors associated with risk of overdose (n = 103) were identified and thematically organised into ten groups. These were: income; housing instability; incarceration; traumatic experiences; overdose risk perception and past experience; healthcare experiences; perception of own drug use and injecting skills; injecting setting; conditions with physical environment; and social network traits. Global rates of overdose continue to increase, and many guidelines recommend psychosocial interventions for dependent drug use. The factors identified here provide useful targets for practitioners to focus on at the individual level, but many identified will require wider policy changes to affect positive change. Future research should seek to develop and trial interventions targeting factors identified, whilst advocacy for key policy reforms to reduce harm must continue.","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study 使用芬太尼者在门诊开始使用低剂量丁丙诺啡期间的戒断情况:一项回顾性队列研究
IF 4.4 2区 社会学 Q1 Medicine Pub Date : 2024-04-09 DOI: 10.1186/s12954-024-00998-9
Benjamin L. H. Jones, Michelle Geier, John Neuhaus, Phillip O. Coffin, Hannah R. Snyder, Christine S. Soran, Kelly R. Knight, Leslie W. Suen
Buprenorphine is an effective treatment for opioid use disorder (OUD); however, buprenorphine initiation can be complicated by withdrawal symptoms including precipitated withdrawal. There has been increasing interest in using low dose initiation (LDI) strategies to reduce this withdrawal risk. As there are limited data on withdrawal symptoms during LDI, we characterize withdrawal symptoms in people with daily fentanyl use who underwent initiation using these strategies as outpatients. We conducted a retrospective chart review of patients with OUD using daily fentanyl who were prescribed 7-day or 4-day LDI at 2 substance use disorder treatment clinics in San Francisco. Two addiction medicine experts assessed extracted chart documentation for withdrawal severity and precipitated withdrawal, defined as acute worsening of withdrawal symptoms immediately after taking buprenorphine. A third expert adjudicated disagreements. Data were analyzed using descriptive statistics. There were 175 initiations in 126 patients. The mean age was 37 (SD 10 years). 71% were men, 26% women, and 2% non-binary. 21% identified as Black, 16% Latine, and 52% white. 60% were unstably housed and 75% had Medicaid insurance. Substance co-use included 74% who used amphetamines, 29% cocaine, 22% benzodiazepines, and 19% alcohol. Follow up was available for 118 (67%) initiations. There was deviation from protocol instructions in 22% of these initiations with follow up. 31% had any withdrawal, including 21% with mild symptoms, 8% moderate and 2% severe. Precipitated withdrawal occurred in 10 cases, or 8% of initiations with follow up. Of these, 7 had deviation from protocol instructions; thus, there were 3 cases with follow up (3%) in which precipitated withdrawal occurred without protocol deviation. Withdrawal was relatively common in our cohort but was mostly mild, and precipitated withdrawal was rare. Deviation from instructions, structural barriers, and varying fentanyl use characteristics may contribute to withdrawal. Clinicians should counsel patients who use fentanyl that mild withdrawal symptoms are likely during LDI, and there is still a low risk for precipitated withdrawal. Future studies should compare withdrawal across initiation types, seek ways to support patients in initiating buprenorphine, and qualitatively elicit patients’ withdrawal experiences.
丁丙诺啡是一种治疗阿片类药物使用障碍(OUD)的有效药物;然而,丁丙诺啡起始治疗可能会因戒断症状(包括沉淀性戒断)而变得复杂。人们越来越关注使用低剂量启动(LDI)策略来降低这种戒断风险。由于有关低剂量起始治疗期间戒断症状的数据有限,我们对门诊患者中每天使用芬太尼并使用这些策略起始治疗的患者的戒断症状进行了分析。我们对旧金山两家药物使用障碍治疗诊所开具 7 天或 4 天 LDI 处方的每日使用芬太尼的 OUD 患者进行了回顾性病历审查。两位成瘾医学专家对提取的病历文件进行了评估,以确定戒断严重程度和析出性戒断,析出性戒断的定义是在服用丁丙诺啡后立即出现急性戒断症状恶化。第三位专家对分歧意见进行裁定。数据采用描述性统计进行分析。共有 126 名患者接受了 175 次治疗。平均年龄为 37 岁(SD 10 岁)。71%为男性,26%为女性,2%为非二元性别。21%为黑人,16%为拉丁裔,52%为白人。60% 的人没有稳定住所,75% 的人有医疗补助保险。滥用药物者包括 74% 的苯丙胺类药物使用者、29% 的可卡因使用者、22% 的苯并二氮杂卓使用者和 19% 的酒精使用者。有 118 人(67%)接受了后续治疗。其中有 22% 的用药者偏离了方案说明,并进行了随访。31%的患者出现了戒断症状,其中21%症状轻微,8%中度,2%重度。有 10 例出现了预兆性停药,占有随访的首次用药的 8%。其中,7 例偏离了方案说明;因此,有 3 例(3%)随访病例在未偏离方案说明的情况下出现了诱发性停药。在我们的队列中,停药现象比较常见,但大多比较轻微,而且很少出现诱发停药的情况。偏离使用说明、结构性障碍和芬太尼使用特点的不同都可能导致戒断。临床医生应告知使用芬太尼的患者,在 LDI 期间可能会出现轻微的戒断症状,而且出现沉淀性戒断的风险仍然很低。未来的研究应比较不同起始类型的戒断情况,寻求支持患者开始使用丁丙诺啡的方法,并从定性角度了解患者的戒断经历。
{"title":"Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study","authors":"Benjamin L. H. Jones, Michelle Geier, John Neuhaus, Phillip O. Coffin, Hannah R. Snyder, Christine S. Soran, Kelly R. Knight, Leslie W. Suen","doi":"10.1186/s12954-024-00998-9","DOIUrl":"https://doi.org/10.1186/s12954-024-00998-9","url":null,"abstract":"Buprenorphine is an effective treatment for opioid use disorder (OUD); however, buprenorphine initiation can be complicated by withdrawal symptoms including precipitated withdrawal. There has been increasing interest in using low dose initiation (LDI) strategies to reduce this withdrawal risk. As there are limited data on withdrawal symptoms during LDI, we characterize withdrawal symptoms in people with daily fentanyl use who underwent initiation using these strategies as outpatients. We conducted a retrospective chart review of patients with OUD using daily fentanyl who were prescribed 7-day or 4-day LDI at 2 substance use disorder treatment clinics in San Francisco. Two addiction medicine experts assessed extracted chart documentation for withdrawal severity and precipitated withdrawal, defined as acute worsening of withdrawal symptoms immediately after taking buprenorphine. A third expert adjudicated disagreements. Data were analyzed using descriptive statistics. There were 175 initiations in 126 patients. The mean age was 37 (SD 10 years). 71% were men, 26% women, and 2% non-binary. 21% identified as Black, 16% Latine, and 52% white. 60% were unstably housed and 75% had Medicaid insurance. Substance co-use included 74% who used amphetamines, 29% cocaine, 22% benzodiazepines, and 19% alcohol. Follow up was available for 118 (67%) initiations. There was deviation from protocol instructions in 22% of these initiations with follow up. 31% had any withdrawal, including 21% with mild symptoms, 8% moderate and 2% severe. Precipitated withdrawal occurred in 10 cases, or 8% of initiations with follow up. Of these, 7 had deviation from protocol instructions; thus, there were 3 cases with follow up (3%) in which precipitated withdrawal occurred without protocol deviation. Withdrawal was relatively common in our cohort but was mostly mild, and precipitated withdrawal was rare. Deviation from instructions, structural barriers, and varying fentanyl use characteristics may contribute to withdrawal. Clinicians should counsel patients who use fentanyl that mild withdrawal symptoms are likely during LDI, and there is still a low risk for precipitated withdrawal. Future studies should compare withdrawal across initiation types, seek ways to support patients in initiating buprenorphine, and qualitatively elicit patients’ withdrawal experiences.","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How do people who use opioids express their qualities and capacities? An assessment of attitudes, behaviors, and opportunities 阿片类药物使用者如何表达自己的素质和能力?对态度、行为和机会的评估
IF 4.4 2区 社会学 Q1 Medicine Pub Date : 2024-04-08 DOI: 10.1186/s12954-024-00981-4
Jerel M. Ezell, Mai T. Pho, Elinor Simek, Babatunde P. Ajayi, Netra Shetty, Suzan M. Walters
People who nonmedically use drugs (PWUD) face intricate social issues that suppress self-actualization, communal integration, and overall health and wellness. “Strengths-based” approaches, an under-used pedagogy and practice in addiction medicine, underscore the significance of identifying and recognizing the inherent and acquired skills, attributes, and capacities of PWUD. A strengths-based approach engenders client affirmation and improves their capacity to reduce drug use-related harms by leveraging existing capabilities. Exploring this paradigm, we conducted and analyzed interviews with 46 PWUD who were clients at syringe services programs in New York City and rural southern Illinois, two areas with elevated rates of opioid-related morbidity and mortality, to assess respondents’ perceived strengths. We located two primary thematic modalities in which strengths-based ethos is expressed: individuals (1) being and advocate and resource for harm reduction knowledge and practices and (2) engaging in acts of continuous self-actualization. These dynamics demonstrate PWUD strengths populating and manifesting in complex ways that both affirm and challenge humanist and biomedical notions of individual agency, as PWUD refract enacted, anticipated, and perceived stigmas. In conclusion, programs that blend evidence-based, systems-level interventions on drug use stigma and disenfranchisement with meso and micro-level strengths-based interventions that affirm and leverage personal identity, decision-making capacity, and endemic knowledge may help disrupt health promotion cleavages among PWUD.
非医疗使用毒品者(PWUD)面临着错综复杂的社会问题,这些问题抑制了他们的自我实现、社区融合以及整体健康和福祉。"基于优势的 "方法是成瘾医学中一种未得到充分利用的教学和实践方法,它强调了识别和认可非药物滥用者固有和后天技能、属性和能力的重要性。以长处为基础的方法使客户得到肯定,并通过利用现有能力提高他们减少吸毒相关危害的能力。在探索这一模式的过程中,我们对纽约市和伊利诺伊州南部农村地区的 46 名注射器服务计划客户进行了访谈并对访谈内容进行了分析,这两个地区的阿片类药物相关发病率和死亡率均有所上升。我们发现,以优势为基础的精神主要体现在两个主题模式上:个人(1)是减低伤害知识和实践的倡导者和资源;(2)参与持续的自我实现行为。这些动态展示了残疾人的优势,并以复杂的方式表现出来,既肯定又挑战了个人能动性的人文主义和生物医学概念,因为残疾人可以折射出已形成的、预期的和感知到的污名。总之,将针对吸毒污名化和剥夺公民权的循证、系统层面的干预措施与肯定和利用个人身份、决策能力和地方性知识的中观和微观层面的基于优势的干预措施相结合的计划,可能有助于打破针对残疾人的健康促进裂痕。
{"title":"How do people who use opioids express their qualities and capacities? An assessment of attitudes, behaviors, and opportunities","authors":"Jerel M. Ezell, Mai T. Pho, Elinor Simek, Babatunde P. Ajayi, Netra Shetty, Suzan M. Walters","doi":"10.1186/s12954-024-00981-4","DOIUrl":"https://doi.org/10.1186/s12954-024-00981-4","url":null,"abstract":"People who nonmedically use drugs (PWUD) face intricate social issues that suppress self-actualization, communal integration, and overall health and wellness. “Strengths-based” approaches, an under-used pedagogy and practice in addiction medicine, underscore the significance of identifying and recognizing the inherent and acquired skills, attributes, and capacities of PWUD. A strengths-based approach engenders client affirmation and improves their capacity to reduce drug use-related harms by leveraging existing capabilities. Exploring this paradigm, we conducted and analyzed interviews with 46 PWUD who were clients at syringe services programs in New York City and rural southern Illinois, two areas with elevated rates of opioid-related morbidity and mortality, to assess respondents’ perceived strengths. We located two primary thematic modalities in which strengths-based ethos is expressed: individuals (1) being and advocate and resource for harm reduction knowledge and practices and (2) engaging in acts of continuous self-actualization. These dynamics demonstrate PWUD strengths populating and manifesting in complex ways that both affirm and challenge humanist and biomedical notions of individual agency, as PWUD refract enacted, anticipated, and perceived stigmas. In conclusion, programs that blend evidence-based, systems-level interventions on drug use stigma and disenfranchisement with meso and micro-level strengths-based interventions that affirm and leverage personal identity, decision-making capacity, and endemic knowledge may help disrupt health promotion cleavages among PWUD.","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An exploratory, randomised, crossover study to investigate the effect of nicotine on cognitive function in healthy adult smokers who use an electronic cigarette after a period of smoking abstinence 一项探索性、随机、交叉研究,旨在调查尼古丁对戒烟一段时间后使用电子烟的健康成年吸烟者认知功能的影响
IF 4.4 2区 社会学 Q1 Medicine Pub Date : 2024-04-06 DOI: 10.1186/s12954-024-00993-0
Harry J. Green, Olivia K. O’Shea, Jack Cotter, Helen L. Philpott, Nik Newland
As well as being associated with serious negative health outcomes, smoking has been reported to have an array of physiological and psychological effects, including effects on mood and cognitive function. Post-cessation, loss of such effects (including temporary deficits in cognitive function) have been cited as reasons for resumption of smoking. The effects of e-cigarettes and nicotine delivered by e-cigarettes on these functions have not been widely researched but may play a role in the effectiveness of e-cigarettes as a satisfactory alternative to combustible cigarettes for people who smoke, and in encouraging individuals who would otherwise continue to smoke, to transition to e-cigarettes. The study was an exploratory, randomised, partially-blinded, single-centre, five-arm crossover trial that recruited 40 healthy male and female people who smoke. At 5 study sessions, following a 12-h period of nicotine abstinence, participants were randomly assigned to use either a combustible cigarette, an e-cigarette of three varying nicotine strengths (18 mg/mL, 12 mg/mL or 0 mg/mL respectively) or observe a no product usage session. Participants completed pre- and post-product usage assessments to examine the product usage effect on cognitive performance (using the Cambridge Neuropsychological Test Automated Battery (CANTAB)), subjective mood and smoking urges. A significant improvement in sustained attention task performance was observed following use of both the nicotine containing e-cigarettes and combustible cigarette compared to no product use. Additionally, there were no significant differences between the nicotine containing products, indicating that nicotine use enhanced sustained attention regardless of delivery format. Nicotine containing e-cigarette and combustible cigarette use also significantly improved overall mood of participants compared to no product use, with no significant differences observed between the nicotine containing products. Nicotine containing e-cigarette and combustible cigarette use significantly reduced smoking urges compared to no product use, though combustible cigarette use elicited the greatest reduction in smoking urges. Overall, the nicotine containing products improved sustained attention and mood while reducing smoking urges, with the studied e-cigarettes having comparable effects to combustible cigarettes across the assessed cognitive parameters and mood measures. These results demonstrate the potential role of e-cigarettes to provide an acceptable alternative for combustible cigarettes among people who would otherwise continue to smoke. Trial registration ISRCTN (identifier: ISRCTN35376793).
据报道,吸烟不仅会对健康造成严重的负面影响,还会产生一系列生理和心理影响,包括对情绪和认知功能的影响。戒烟后,失去这些影响(包括认知功能的暂时缺陷)被认为是重新吸烟的原因。电子烟和电子烟提供的尼古丁对这些功能的影响尚未得到广泛研究,但可能对电子烟作为吸烟者满意的可燃卷烟替代品的有效性,以及鼓励原本会继续吸烟的人过渡到电子烟起到一定作用。该研究是一项探索性、随机、部分盲法、单中心、五臂交叉试验,共招募了 40 名健康的男性和女性吸烟者。在5次研究过程中,在禁用尼古丁12小时后,参与者被随机分配使用可燃卷烟、三种不同尼古丁强度(分别为18毫克/毫升、12毫克/毫升或0毫克/毫升)的电子烟或观察不使用产品的过程。参与者完成产品使用前后的评估,以检查产品使用对认知能力(使用剑桥神经心理测试自动化电池(CANTAB))、主观情绪和吸烟冲动的影响。与不使用产品相比,使用含有尼古丁的电子烟和可燃卷烟后,受试者的持续注意力任务表现均有明显改善。此外,含有尼古丁的产品之间没有明显差异,这表明使用尼古丁会增强持续注意力,而与给药形式无关。与不使用产品相比,使用含尼古丁的电子烟和可燃卷烟也能显著改善参与者的整体情绪,含尼古丁的产品之间没有明显差异。与不使用产品相比,使用含尼古丁的电子烟和可燃卷烟能明显减少吸烟冲动,但使用可燃卷烟能最大程度地减少吸烟冲动。总体而言,含有尼古丁的产品在减少吸烟冲动的同时还能改善持续注意力和情绪,所研究的电子烟在认知参数和情绪测量方面的效果与可燃卷烟相当。这些结果表明,电子烟可以替代可燃卷烟,为继续吸烟者提供一种可接受的选择。试验注册 ISRCTN(标识符:ISRCTN35376793)。
{"title":"An exploratory, randomised, crossover study to investigate the effect of nicotine on cognitive function in healthy adult smokers who use an electronic cigarette after a period of smoking abstinence","authors":"Harry J. Green, Olivia K. O’Shea, Jack Cotter, Helen L. Philpott, Nik Newland","doi":"10.1186/s12954-024-00993-0","DOIUrl":"https://doi.org/10.1186/s12954-024-00993-0","url":null,"abstract":"As well as being associated with serious negative health outcomes, smoking has been reported to have an array of physiological and psychological effects, including effects on mood and cognitive function. Post-cessation, loss of such effects (including temporary deficits in cognitive function) have been cited as reasons for resumption of smoking. The effects of e-cigarettes and nicotine delivered by e-cigarettes on these functions have not been widely researched but may play a role in the effectiveness of e-cigarettes as a satisfactory alternative to combustible cigarettes for people who smoke, and in encouraging individuals who would otherwise continue to smoke, to transition to e-cigarettes. The study was an exploratory, randomised, partially-blinded, single-centre, five-arm crossover trial that recruited 40 healthy male and female people who smoke. At 5 study sessions, following a 12-h period of nicotine abstinence, participants were randomly assigned to use either a combustible cigarette, an e-cigarette of three varying nicotine strengths (18 mg/mL, 12 mg/mL or 0 mg/mL respectively) or observe a no product usage session. Participants completed pre- and post-product usage assessments to examine the product usage effect on cognitive performance (using the Cambridge Neuropsychological Test Automated Battery (CANTAB)), subjective mood and smoking urges. A significant improvement in sustained attention task performance was observed following use of both the nicotine containing e-cigarettes and combustible cigarette compared to no product use. Additionally, there were no significant differences between the nicotine containing products, indicating that nicotine use enhanced sustained attention regardless of delivery format. Nicotine containing e-cigarette and combustible cigarette use also significantly improved overall mood of participants compared to no product use, with no significant differences observed between the nicotine containing products. Nicotine containing e-cigarette and combustible cigarette use significantly reduced smoking urges compared to no product use, though combustible cigarette use elicited the greatest reduction in smoking urges. Overall, the nicotine containing products improved sustained attention and mood while reducing smoking urges, with the studied e-cigarettes having comparable effects to combustible cigarettes across the assessed cognitive parameters and mood measures. These results demonstrate the potential role of e-cigarettes to provide an acceptable alternative for combustible cigarettes among people who would otherwise continue to smoke. Trial registration ISRCTN (identifier: ISRCTN35376793).","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relationship between felt stigma and non-fatal overdose among rural people who use drugs 农村吸毒者的耻辱感与非致命性吸毒过量之间的关系
IF 4.4 2区 社会学 Q1 Medicine Pub Date : 2024-04-06 DOI: 10.1186/s12954-024-00988-x
Adams L. Sibley, Emma Klein, Hannah L.F. Cooper, Melvin D. Livingston, Robin Baker, Suzan M. Walters, Rachel E. Gicquelais, Stephanie A. Ruderman, Peter D. Friedmann, Wiley D. Jenkins, Vivian F. Go, William C. Miller, Ryan P. Westergaard, Heidi M Crane
Drug overdose deaths in the United States exceeded 100,000 in 2021 and 2022. Substance use stigma is a major barrier to treatment and harm reduction utilization and is a priority target in ending the overdose epidemic. However, little is known about the relationship between stigma and overdose, especially in rural areas. We aimed to characterize the association between felt stigma and non-fatal overdose in a multi-state sample of rural-dwelling people who use drugs. Between January 2018 and March 2020, 2,608 people reporting past 30-day opioid use were recruited via modified chain-referral sampling in rural areas across 10 states. Participants completed a computer-assisted survey of substance use and substance-related attitudes, behaviors, and experiences. We used multivariable logistic regression with generalized estimating equations to test the association between felt stigma and recent non-fatal overdose. 6.6% of participants (n = 173) reported an overdose in the past 30 days. Recent non-fatal overdose was significantly associated with felt stigma after adjusting for demographic and substance use-related covariates (aOR: 1.47, 95% CI: 1.20–1.81). The association remained significant in sensitivity analyses on component fear of enacted stigma items (aOR: 1.48, 95% CI: 1.20–1.83) and an internalized stigma item (aOR: 1.51, 95% CI: 1.07–2.14). Felt stigma related to substance use is associated with higher risk of non-fatal overdose in rural-dwelling people who use drugs. Stigma reduction interventions and tailored services for those experiencing high stigma are underutilized approaches that may mitigate overdose risk.
2021 年和 2022 年,美国吸毒过量死亡人数超过 10 万。药物使用污名化是治疗和减低伤害利用率的主要障碍,也是结束用药过量流行的优先目标。然而,人们对污名化与用药过量之间的关系知之甚少,尤其是在农村地区。我们的目标是在一个多州的农村吸毒者样本中,描述感受到的污名化与非致死性用药过量之间的关系。2018 年 1 月至 2020 年 3 月期间,我们在 10 个州的农村地区通过修改后的连锁转介抽样招募了 2608 名报告过去 30 天使用过阿片类药物的人。参与者完成了一项关于药物使用和药物相关态度、行为和经历的计算机辅助调查。我们使用广义估计方程的多变量逻辑回归来检验感受到的污名化与近期非致命性用药过量之间的关联。6.6%的参与者(n = 173)报告在过去 30 天内用药过量。在对人口统计学和药物使用相关协变量进行调整后,近期非致命性用药过量与感受到的耻辱感有显著关联(aOR:1.47,95% CI:1.20-1.81)。在对 "对颁布成见的恐惧 "项目(aOR:1.48,95% CI:1.20-1.83)和 "内化成见 "项目(aOR:1.51,95% CI:1.07-2.14)进行敏感性分析后,两者之间的关系仍然显著。在农村居住的吸毒者中,与药物使用相关的耻辱感与较高的非致命性用药过量风险有关。减少污名化的干预措施和为遭受严重污名化的人提供量身定制的服务是一种未得到充分利用的方法,可降低用药过量的风险。
{"title":"The relationship between felt stigma and non-fatal overdose among rural people who use drugs","authors":"Adams L. Sibley, Emma Klein, Hannah L.F. Cooper, Melvin D. Livingston, Robin Baker, Suzan M. Walters, Rachel E. Gicquelais, Stephanie A. Ruderman, Peter D. Friedmann, Wiley D. Jenkins, Vivian F. Go, William C. Miller, Ryan P. Westergaard, Heidi M Crane","doi":"10.1186/s12954-024-00988-x","DOIUrl":"https://doi.org/10.1186/s12954-024-00988-x","url":null,"abstract":"Drug overdose deaths in the United States exceeded 100,000 in 2021 and 2022. Substance use stigma is a major barrier to treatment and harm reduction utilization and is a priority target in ending the overdose epidemic. However, little is known about the relationship between stigma and overdose, especially in rural areas. We aimed to characterize the association between felt stigma and non-fatal overdose in a multi-state sample of rural-dwelling people who use drugs. Between January 2018 and March 2020, 2,608 people reporting past 30-day opioid use were recruited via modified chain-referral sampling in rural areas across 10 states. Participants completed a computer-assisted survey of substance use and substance-related attitudes, behaviors, and experiences. We used multivariable logistic regression with generalized estimating equations to test the association between felt stigma and recent non-fatal overdose. 6.6% of participants (n = 173) reported an overdose in the past 30 days. Recent non-fatal overdose was significantly associated with felt stigma after adjusting for demographic and substance use-related covariates (aOR: 1.47, 95% CI: 1.20–1.81). The association remained significant in sensitivity analyses on component fear of enacted stigma items (aOR: 1.48, 95% CI: 1.20–1.83) and an internalized stigma item (aOR: 1.51, 95% CI: 1.07–2.14). Felt stigma related to substance use is associated with higher risk of non-fatal overdose in rural-dwelling people who use drugs. Stigma reduction interventions and tailored services for those experiencing high stigma are underutilized approaches that may mitigate overdose risk.","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont 佛蒙特州伯灵顿市减低危害服务接受者的药物使用模式、社会人口学和健康概况
IF 4.4 2区 社会学 Q1 Medicine Pub Date : 2024-04-05 DOI: 10.1186/s12954-024-00995-y
Tyler G. Erath, Rosalie LaCroix, Erin O’Keefe, Stephen T. Higgins, Richard A. Rawson
Understanding current substance use practices is critical to reduce and prevent overdose deaths among individuals at increased risk including persons who use and inject drugs. Because individuals participating in harm reduction and syringe service programs are actively using drugs and vary in treatment participation, information on their current drug use and preferred drugs provides a unique window into the drug use ecology of communities that can inform future intervention services and treatment provision. Between March and June 2023, 150 participants in a harm reduction program in Burlington, Vermont completed a survey examining sociodemographics; treatment and medication for opioid use disorder (MOUD) status; substance use; injection information; overdose information; and mental health, medical, and health information. Descriptive analyses assessed overall findings. Comparisons between primary drug subgroups (stimulants, opioids, stimulants-opioids) of past-three-month drug use and treatment participation were analyzed using chi-square and Fisher’s exact test. Most participants reported being unhoused or unstable housing (80.7%) and unemployed (64.0%) or on disability (21.3%). The drug with the greatest proportion of participants reporting past three-month use was crack cocaine (83.3%). Fentanyl use was reported by 69.3% of participants and xylazine by 38.0% of participants. High rates of stimulant use were reported across all participants independent of whether stimulants were a participant’s primary drug. Fentanyl, heroin, and xylazine use was less common in the stimulants subgroup compared to opioid-containing subgroups (p < .001). Current- and past-year MOUD treatment was reported by 58.0% and 77.3% of participants. Emergency rooms were the most common past-year medical treatment location (48.7%; M = 2.72 visits). Findings indicate high rates of polysubstance use and the underrecognized effects of stimulant use among people who use drugs—including its notable and increasing role in drug-overdose deaths. Crack cocaine was the most used stimulant, a geographical difference from much of the US where methamphetamine is most common. With the increasing prevalence of fentanyl-adulterated stimulants and differences in opioid use observed between subgroups, these findings highlight the importance and necessity of harm reduction interventions (e.g., drug checking services, fentanyl test strips) and effective treatment for individuals using stimulants alongside MOUD treatment.
了解当前的药物使用习惯对于减少和预防包括吸食和注射毒品者在内的高危人群的用药过量死亡至关重要。由于参与减低伤害和注射器服务计划的人都在积极使用毒品,而且参与治疗的情况也不尽相同,因此有关他们当前使用毒品和偏好药物的信息为了解社区的毒品使用生态提供了一个独特的窗口,可以为未来的干预服务和治疗提供参考。2023 年 3 月至 6 月间,佛蒙特州伯灵顿市一项减低伤害计划的 150 名参与者完成了一项调查,调查内容包括社会人口统计学、阿片类药物使用障碍(MOUD)的治疗和用药情况、药物使用情况、注射信息、用药过量信息以及精神健康、医疗和保健信息。描述性分析评估了总体调查结果。使用卡方检验(chi-square)和费雪精确检验(Fisher's exact test)分析了主要药物亚组(兴奋剂、类阿片、兴奋剂-类阿片)之间过去三个月药物使用和治疗参与情况的比较。大多数参与者表示没有住房或住房不稳定(80.7%)、失业(64.0%)或残疾(21.3%)。报告在过去三个月中吸食毒品比例最高的是快克可卡因(83.3%)。69.3%的参与者报告使用过芬太尼,38.0%的参与者报告使用过羟嗪。所有参与者都报告了较高的兴奋剂使用率,与兴奋剂是否是参与者的主要毒品无关。与含有阿片类药物的分组相比,兴奋剂分组中使用芬太尼、海洛因和异丙嗪的比例较低(p < .001)。58.0% 和 77.3% 的参与者报告了当前和过去一年的 MOUD 治疗情况。急诊室是过去一年中最常见的医疗地点(48.7%;M = 2.72 次)。研究结果表明,在吸毒者中,多种物质的使用率很高,而且人们对使用兴奋剂的影响认识不足,包括兴奋剂在吸毒过量死亡中所起的显著和日益增加的作用。快克可卡因是使用最多的兴奋剂,这与甲基苯丙胺最常见的美国大部分地区存在地域差异。随着掺有芬太尼的兴奋剂使用率的增加,以及观察到的不同亚群之间阿片类药物使用的差异,这些研究结果凸显了减少危害干预措施(如药物检查服务、芬太尼检测条)和对使用兴奋剂的个人进行有效治疗的重要性和必要性,同时也凸显了钼靶治疗的重要性和必要性。
{"title":"Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont","authors":"Tyler G. Erath, Rosalie LaCroix, Erin O’Keefe, Stephen T. Higgins, Richard A. Rawson","doi":"10.1186/s12954-024-00995-y","DOIUrl":"https://doi.org/10.1186/s12954-024-00995-y","url":null,"abstract":"Understanding current substance use practices is critical to reduce and prevent overdose deaths among individuals at increased risk including persons who use and inject drugs. Because individuals participating in harm reduction and syringe service programs are actively using drugs and vary in treatment participation, information on their current drug use and preferred drugs provides a unique window into the drug use ecology of communities that can inform future intervention services and treatment provision. Between March and June 2023, 150 participants in a harm reduction program in Burlington, Vermont completed a survey examining sociodemographics; treatment and medication for opioid use disorder (MOUD) status; substance use; injection information; overdose information; and mental health, medical, and health information. Descriptive analyses assessed overall findings. Comparisons between primary drug subgroups (stimulants, opioids, stimulants-opioids) of past-three-month drug use and treatment participation were analyzed using chi-square and Fisher’s exact test. Most participants reported being unhoused or unstable housing (80.7%) and unemployed (64.0%) or on disability (21.3%). The drug with the greatest proportion of participants reporting past three-month use was crack cocaine (83.3%). Fentanyl use was reported by 69.3% of participants and xylazine by 38.0% of participants. High rates of stimulant use were reported across all participants independent of whether stimulants were a participant’s primary drug. Fentanyl, heroin, and xylazine use was less common in the stimulants subgroup compared to opioid-containing subgroups (p < .001). Current- and past-year MOUD treatment was reported by 58.0% and 77.3% of participants. Emergency rooms were the most common past-year medical treatment location (48.7%; M = 2.72 visits). Findings indicate high rates of polysubstance use and the underrecognized effects of stimulant use among people who use drugs—including its notable and increasing role in drug-overdose deaths. Crack cocaine was the most used stimulant, a geographical difference from much of the US where methamphetamine is most common. With the increasing prevalence of fentanyl-adulterated stimulants and differences in opioid use observed between subgroups, these findings highlight the importance and necessity of harm reduction interventions (e.g., drug checking services, fentanyl test strips) and effective treatment for individuals using stimulants alongside MOUD treatment.","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding access to healthcare for people who use drugs and sex workers: hepatitis C elimination implications from a qualitative study of healthcare experiences in British Columbia, Canada 扩大吸毒者和性工作者获得医疗保健的机会:对加拿大不列颠哥伦比亚省医疗保健经验的定性研究对消除丙型肝炎的影响
IF 4.4 2区 社会学 Q1 Medicine Pub Date : 2024-04-04 DOI: 10.1186/s12954-024-00991-2
Nance E. Cunningham, Jessica Lamb, Amanda Staller, Mel Krajden, Robert S. Hogg, Angela Towle, Viviane Dias Lima, Kate Salters
Hepatitis C virus (HCV) is a major health threat in Canada. In British Columbia (BC) province, 1.6% of the population had been exposed to HCV by 2012. Prevalence and incidence of HCV are very high in populations of people who use drugs (PWUD) and sex workers (SW), who may experience unique barriers to healthcare. Consequently, they are less likely to be treated for HCV. Overcoming these barriers is critical for HCV elimination. This research sought to explore the healthcare experiences of PWUD and SW and how these experiences impact their willingness to engage in healthcare in the future, including HCV care. Interpretive Description guided this qualitative study of healthcare experiences in BC, underpinned by the Health Stigma and Discrimination framework. The study team included people with living/lived experience of drug use, sex work, and HCV. Twenty-five participants completed in-depth semi-structured interviews on their previous healthcare and HCV-related experiences. Thematic analysis was used to identify common themes. Three major themes were identified in our analysis. First, participants reported common experiences of delay and refusal of care by healthcare providers, with many negative healthcare encounters perceived as rooted in institutional culture reflecting societal stigma. Second, participants discussed their choice to engage in or avoid healthcare. Many avoided all but emergency care following negative experiences in any kind of healthcare. Third, participants described the roles of respect, stigma, dignity, fear, and trust in communication in healthcare relationships. Healthcare experiences shared by participants pointed to ways that better understanding and communication by healthcare providers could support positive change in healthcare encounters of PWUD and SW, who are at high risk of HCV infection. More positive healthcare encounters could lead to increased healthcare engagement which is essential for HCV elimination.
丙型肝炎病毒(HCV)是加拿大的一大健康威胁。截至 2012 年,不列颠哥伦比亚省(BC 省)有 1.6% 的人口感染了丙型肝炎病毒。在吸毒者(PWUD)和性工作者(SW)人群中,丙型肝炎病毒的流行率和发病率都非常高,他们可能会遇到独特的医疗保健障碍。因此,他们接受 HCV 治疗的可能性较低。克服这些障碍对于消灭 HCV 至关重要。本研究旨在探讨残疾人和性工作者的医疗保健经历,以及这些经历如何影响他们今后参与医疗保健(包括 HCV 护理)的意愿。解释性说明以健康污名化和歧视框架为基础,对不列颠哥伦比亚省的医疗保健经历进行了定性研究。研究小组成员包括有吸毒、性工作和丙型肝炎病毒生活/生命经历的人。25 名参与者就其以往的医疗保健和 HCV 相关经历完成了深入的半结构化访谈。我们采用了主题分析法来确定共同的主题。我们的分析确定了三大主题。首先,参与者报告了医疗服务提供者拖延和拒绝提供医疗服务的共同经历,其中许多负面的医疗遭遇被认为源于反映社会污名化的机构文化。其次,参与者讨论了他们参与或避免医疗保健的选择。许多人在经历了任何一种医疗保健的负面经历之后,除了急诊之外,都避免了其他任何医疗保健。第三,与会者描述了尊重、耻辱、尊严、恐惧和信任在医疗保健关系沟通中的作用。与会者分享的医疗保健经验表明,医疗保健提供者通过更好地理解和沟通,可以帮助感染丙型肝炎病毒的高危人群(PWUD 和 SW)在医疗保健接触中发生积极变化。更积极的医疗保健接触可提高医疗保健参与度,这对消除丙型肝炎病毒至关重要。
{"title":"Expanding access to healthcare for people who use drugs and sex workers: hepatitis C elimination implications from a qualitative study of healthcare experiences in British Columbia, Canada","authors":"Nance E. Cunningham, Jessica Lamb, Amanda Staller, Mel Krajden, Robert S. Hogg, Angela Towle, Viviane Dias Lima, Kate Salters","doi":"10.1186/s12954-024-00991-2","DOIUrl":"https://doi.org/10.1186/s12954-024-00991-2","url":null,"abstract":"Hepatitis C virus (HCV) is a major health threat in Canada. In British Columbia (BC) province, 1.6% of the population had been exposed to HCV by 2012. Prevalence and incidence of HCV are very high in populations of people who use drugs (PWUD) and sex workers (SW), who may experience unique barriers to healthcare. Consequently, they are less likely to be treated for HCV. Overcoming these barriers is critical for HCV elimination. This research sought to explore the healthcare experiences of PWUD and SW and how these experiences impact their willingness to engage in healthcare in the future, including HCV care. Interpretive Description guided this qualitative study of healthcare experiences in BC, underpinned by the Health Stigma and Discrimination framework. The study team included people with living/lived experience of drug use, sex work, and HCV. Twenty-five participants completed in-depth semi-structured interviews on their previous healthcare and HCV-related experiences. Thematic analysis was used to identify common themes. Three major themes were identified in our analysis. First, participants reported common experiences of delay and refusal of care by healthcare providers, with many negative healthcare encounters perceived as rooted in institutional culture reflecting societal stigma. Second, participants discussed their choice to engage in or avoid healthcare. Many avoided all but emergency care following negative experiences in any kind of healthcare. Third, participants described the roles of respect, stigma, dignity, fear, and trust in communication in healthcare relationships. Healthcare experiences shared by participants pointed to ways that better understanding and communication by healthcare providers could support positive change in healthcare encounters of PWUD and SW, who are at high risk of HCV infection. More positive healthcare encounters could lead to increased healthcare engagement which is essential for HCV elimination.","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acceptability of a pilot motivational interviewing intervention at public health facilities to improve the HIV treatment cascade among people who inject drugs in Indonesia. 印度尼西亚公共卫生机构为改善注射吸毒者中的艾滋病治疗级联而开展的试点动机访谈干预的可接受性。
IF 4 2区 社会学 Q1 SUBSTANCE ABUSE Pub Date : 2024-04-01 DOI: 10.1186/s12954-024-00989-w
Lydia V Wongso, Arie Rahadi, Evi Sukmaningrum, Miasari Handayani, Rudi Wisaksana

Background: HIV-positive people who inject drugs (PWID) experience challenges in initiating and adhering to antiretroviral treatment (ART). Counselling using motivational interviewing (MI) techniques may help them formulate individualised strategies, and execute actions to address these challenges collaboratively with their providers. We evaluated the acceptability of MI from a pilot implementation at three public health facilities in Indonesia.

Methods: Adapting the acceptability constructs developed by Sekhon (2017) we assessed the acceptability to HIV-positive PWID clients (n = 12) and providers (n = 10) in four synthesised constructs: motivation (attributes that inspire engagement); cost consideration (sacrifices made to engage in MI); learned understanding (mechanism of action); and outcomes (ability to effect change with engagement). We included all providers and clients who completed ≥ 2 MI encounters. Qualitative analysis with an interpretive paradigm was used to extract and categorise themes by these constructs.

Results: In motivation, clients valued the open communication style of MI, while providers appreciated its novelty in offering coherent structure with clear boundaries. In cost consideration, both groups faced a challenge in meeting MI encounters due to access or engagement in other health care areas. In learned understanding, clients understood that MI worked to identify problematic areas of life amenable to change to support long-term ART, with reconciliation in family life being the most targeted change. By contrast, providers preferred targeting tangible health outcomes to such behavioural proxies. In outcomes, clients were confident in their ability to develop behaviours to sustain ART uptakes, whereas providers doubted the outcome of MI on younger PWID or those with severe dependence.

Conclusions: There is broad acceptability of MI in motivating engagement for both actors. Relative to providers, clients were more acceptable in its mechanism and had greater confidence to perform behaviours conducive to ART engagement. Design innovations to improve the acceptability of MI for both actors are needed.

背景:艾滋病毒呈阳性的注射吸毒者(PWID)在开始和坚持抗逆转录病毒治疗(ART)方面面临挑战。使用动机访谈(MI)技术进行咨询可帮助他们制定个性化策略,并与医疗服务提供者合作采取行动应对这些挑战。我们评估了印度尼西亚三家公共医疗机构试点实施的动机访谈法的可接受性:我们对 Sekhon(2017 年)开发的可接受性结构进行了调整,评估了艾滋病毒呈阳性的感染者客户(n = 12)和服务提供者(n = 10)对以下四个综合结构的可接受性:动机(激发参与的属性);成本考虑(为参与多元智能而做出的牺牲);学习理解(作用机制);以及结果(通过参与实现改变的能力)。我们将所有完成了 ≥ 2 次参与式管理的医疗服务提供者和客户都包括在内。我们采用了解释性范式的定性分析方法,根据这些构建要素提取主题并进行分类:结果:在动机方面,客户重视多元智能的开放式沟通风格,而提供者则赞赏其提供了边界清晰的连贯结构的新颖性。在成本考虑方面,两组人都面临着因交通不便或参与其他医疗保健领域而无法满足多元智能需求的挑战。在学习理解方面,客户理解多元智能的工作是找出生活中存在问题的领域,并加以改变,以支持长期抗逆转录病毒疗法,而家庭生活的协调是最有针对性的改变。相比之下,医疗服务提供者更倾向于以有形的健康成果为目标,而不是这些行为代用指标。在结果方面,受试者对自己发展行为以维持抗逆转录病毒疗法的能力充满信心,而提供者则怀疑管理疗法对年轻的吸毒者或严重依赖者的效果:结论:在激励双方参与方面,MI 具有广泛的可接受性。相对于医疗服务提供者,患者更容易接受其机制,也更有信心做出有利于参与抗逆转录病毒疗法的行为。需要进行设计创新,以提高双方对管理信息系统的接受度。
{"title":"Acceptability of a pilot motivational interviewing intervention at public health facilities to improve the HIV treatment cascade among people who inject drugs in Indonesia.","authors":"Lydia V Wongso, Arie Rahadi, Evi Sukmaningrum, Miasari Handayani, Rudi Wisaksana","doi":"10.1186/s12954-024-00989-w","DOIUrl":"10.1186/s12954-024-00989-w","url":null,"abstract":"<p><strong>Background: </strong>HIV-positive people who inject drugs (PWID) experience challenges in initiating and adhering to antiretroviral treatment (ART). Counselling using motivational interviewing (MI) techniques may help them formulate individualised strategies, and execute actions to address these challenges collaboratively with their providers. We evaluated the acceptability of MI from a pilot implementation at three public health facilities in Indonesia.</p><p><strong>Methods: </strong>Adapting the acceptability constructs developed by Sekhon (2017) we assessed the acceptability to HIV-positive PWID clients (n = 12) and providers (n = 10) in four synthesised constructs: motivation (attributes that inspire engagement); cost consideration (sacrifices made to engage in MI); learned understanding (mechanism of action); and outcomes (ability to effect change with engagement). We included all providers and clients who completed ≥ 2 MI encounters. Qualitative analysis with an interpretive paradigm was used to extract and categorise themes by these constructs.</p><p><strong>Results: </strong>In motivation, clients valued the open communication style of MI, while providers appreciated its novelty in offering coherent structure with clear boundaries. In cost consideration, both groups faced a challenge in meeting MI encounters due to access or engagement in other health care areas. In learned understanding, clients understood that MI worked to identify problematic areas of life amenable to change to support long-term ART, with reconciliation in family life being the most targeted change. By contrast, providers preferred targeting tangible health outcomes to such behavioural proxies. In outcomes, clients were confident in their ability to develop behaviours to sustain ART uptakes, whereas providers doubted the outcome of MI on younger PWID or those with severe dependence.</p><p><strong>Conclusions: </strong>There is broad acceptability of MI in motivating engagement for both actors. Relative to providers, clients were more acceptable in its mechanism and had greater confidence to perform behaviours conducive to ART engagement. Design innovations to improve the acceptability of MI for both actors are needed.</p>","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140335412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry. 美国农村地区吸毒者同时使用兴奋剂和阿片类药物的动机和背景:多地点定性调查。
IF 4 2区 社会学 Q1 SUBSTANCE ABUSE Pub Date : 2024-04-01 DOI: 10.1186/s12954-024-00986-z
R J Fredericksen, R Baker, A Sibley, A T Estadt, D Colston, L S Mixson, S Walters, J Bresett, X A Levander, G Leichtling, T Davy-Mendez, M Powell, T J Stopka, M Pho, J Feinberg, J Ezell, W Zule, D Seal, H L F Cooper, B M Whitney, J A C Delaney, H M Crane, J I Tsui

Background: In recent years, stimulant use has increased among persons who use opioids in the rural U.S., leading to high rates of overdose and death. We sought to understand motivations and contexts for stimulant use among persons who use opioids in a large, geographically diverse sample of persons who use drugs (PWUD) in the rural settings.

Methods: We conducted semi-structured individual interviews with PWUD at 8 U.S. sites spanning 10 states and 65 counties. Content areas included general substance use, injection drug use, changes in drug use, and harm reduction practices. We used an iterative open-coding process to comprehensively itemize and categorize content shared by participants related to concurrent use.

Results: We interviewed 349 PWUD (64% male, mean age 36). Of those discussing current use of stimulants in the context of opioid use (n = 137, 39%), the stimulant most used was methamphetamine (78%) followed by cocaine/crack (26%). Motivations for co-use included: 1) change in drug markets and cost considerations; 2) recreational goals, e.g., seeking stronger effects after heightened opioid tolerance; 3) practical goals, such as a desire to balance or alleviate the effects of the other drug, including the use of stimulants to avoid/reverse opioid overdose, and/or control symptoms of opioid withdrawal; and 4) functional goals, such as being simultaneously energized and pain-free in order to remain productive for employment.

Conclusion: In a rural U.S. cohort of PWUD, use of both stimulants and opioids was highly prevalent. Reasons for dual use found in the rural context compared to urban studies included changes in drug availability, functional/productivity goals, and the use of methamphetamine to offset opioid overdose. Education efforts and harm reduction services and treatment, such as access to naloxone, fentanyl test strips, and accessible drug treatment for combined opioid and stimulant use, are urgently needed in the rural U.S. to reduce overdose and other adverse outcomes.

背景:近年来,美国农村地区阿片类药物使用者使用兴奋剂的情况有所增加,导致用药过量和死亡率居高不下。我们试图通过大量不同地域的农村吸毒者样本,了解阿片类药物使用者使用兴奋剂的动机和背景:我们在美国横跨 10 个州和 65 个县的 8 个地点对 PWUD 进行了半结构化个人访谈。内容包括一般药物使用、注射药物使用、药物使用的变化以及减少伤害的做法。我们采用了迭代开放式编码流程,对参与者分享的与同时使用药物相关的内容进行了全面的条目化和分类:我们采访了 349 名吸毒和残障人士(64% 为男性,平均年龄为 36 岁)。在讨论目前在使用阿片类药物的情况下使用兴奋剂的参与者中(n = 137,39%),使用最多的兴奋剂是甲基苯丙胺(78%),其次是可卡因/快克(26%)。共同使用的动机包括1)毒品市场的变化和成本考虑;2)娱乐目标,如在阿片类药物耐受性增强后寻求更强的效果;3)实际目标,如希望平衡或减轻另一种药物的效果,包括使用兴奋剂来避免/逆转阿片类药物过量,和/或控制阿片类药物戒断症状;以及4)功能目标,如同时保持精力充沛和无痛,以保持工作效率:结论:在美国农村地区的吸毒和非法药物滥用者群体中,同时使用兴奋剂和阿片类药物的情况非常普遍。与城市研究相比,在农村发现的双重使用原因包括药物供应的变化、功能/生产力目标以及使用甲基苯丙胺来抵消阿片类药物过量。美国农村地区亟需开展教育工作并提供减少危害的服务和治疗,如提供纳洛酮、芬太尼试纸,以及针对阿片类药物和兴奋剂混合使用的无障碍戒毒治疗,以减少用药过量和其他不良后果。
{"title":"Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry.","authors":"R J Fredericksen, R Baker, A Sibley, A T Estadt, D Colston, L S Mixson, S Walters, J Bresett, X A Levander, G Leichtling, T Davy-Mendez, M Powell, T J Stopka, M Pho, J Feinberg, J Ezell, W Zule, D Seal, H L F Cooper, B M Whitney, J A C Delaney, H M Crane, J I Tsui","doi":"10.1186/s12954-024-00986-z","DOIUrl":"10.1186/s12954-024-00986-z","url":null,"abstract":"<p><strong>Background: </strong>In recent years, stimulant use has increased among persons who use opioids in the rural U.S., leading to high rates of overdose and death. We sought to understand motivations and contexts for stimulant use among persons who use opioids in a large, geographically diverse sample of persons who use drugs (PWUD) in the rural settings.</p><p><strong>Methods: </strong>We conducted semi-structured individual interviews with PWUD at 8 U.S. sites spanning 10 states and 65 counties. Content areas included general substance use, injection drug use, changes in drug use, and harm reduction practices. We used an iterative open-coding process to comprehensively itemize and categorize content shared by participants related to concurrent use.</p><p><strong>Results: </strong>We interviewed 349 PWUD (64% male, mean age 36). Of those discussing current use of stimulants in the context of opioid use (n = 137, 39%), the stimulant most used was methamphetamine (78%) followed by cocaine/crack (26%). Motivations for co-use included: 1) change in drug markets and cost considerations; 2) recreational goals, e.g., seeking stronger effects after heightened opioid tolerance; 3) practical goals, such as a desire to balance or alleviate the effects of the other drug, including the use of stimulants to avoid/reverse opioid overdose, and/or control symptoms of opioid withdrawal; and 4) functional goals, such as being simultaneously energized and pain-free in order to remain productive for employment.</p><p><strong>Conclusion: </strong>In a rural U.S. cohort of PWUD, use of both stimulants and opioids was highly prevalent. Reasons for dual use found in the rural context compared to urban studies included changes in drug availability, functional/productivity goals, and the use of methamphetamine to offset opioid overdose. Education efforts and harm reduction services and treatment, such as access to naloxone, fentanyl test strips, and accessible drug treatment for combined opioid and stimulant use, are urgently needed in the rural U.S. to reduce overdose and other adverse outcomes.</p>","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140335413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of hospital-based substance use supports on emergency department revisits: a retrospective cohort study in Sudbury, Canada from 2018 to 2022 基于医院的药物使用支持与急诊科复诊的关联:2018 年至 2022 年在加拿大萨德伯里开展的一项回顾性队列研究
IF 4.4 2区 社会学 Q1 Medicine Pub Date : 2024-03-28 DOI: 10.1186/s12954-024-00985-0
Mark Tatangelo, Russell Landry, Denis Beaulieu, Catherine Watson, Shannon Knowlan, Alex Anawati, Adele Bodson, Natalie Aubin, David C. Marsh, Tara Leary, Kristen A. Morin
This study compares emergency department (ED) revisits for patients receiving hospital-based substance-use support compared to those who did not receive specialized addiction services at Health Sciences North in Sudbury, Ontario, Canada. The study is a retrospective observational study using administrative data from all patients presenting with substance use disorder (SUD) at Health Sciences North from January 1, 2018, and August 31, 2022 with ICD-10 codes from the Discharge Abstract Database (DAD) and the National Ambulatory Care Database (NACRS). There were two interventions under study: addiction medicine consult services (AMCS group), and specialized addiction medicine unit (AMU group). The AMCS is a consult service offered for patients in the ED and those who are admitted to the hospital. The AMU is a specialized inpatient medical unit designed to offer addiction support to stabilize patients that operates under a harm-reduction philosophy. The primary outcome was all cause ED revisit within 30 days of the index ED or hospital visit. The secondary outcome was all observed ED revisits in the study period. Kaplan–Meier curves were used to measure the proportion of 30-day revisits by exposure group. Odds ratios and Hazard Ratios were calculated using logistic regression models with random effects and Cox-proportional hazard model respectively. A total of 5,367 patients with 10,871 ED index visits, and 2,127 revisits between 2018 and 2022 are included in the study. 45% (2,340/5,367) of patient were not admitted to hospital. 30-day revisits were less likely among the intervention group: Addiction Medicine Consult Services (AMCS) in the ED significantly reduced the odds of revisits (OR 0.53, 95% CI 0.39–0.71, p < 0.01) and first revisits (OR 0.42, 95% CI 0.33–0.53, p < 0.01). The AMU group was associated with lower revisits odds (OR 0.80, 95% CI 0.66–0.98, p = 0.03). For every additional year of age, the odds of revisits slightly decreased (OR 0.99, 95% CI 0.98–1.00, p = 0.01) and males were found to have an increased risk compared to females (OR 1.50, 95% CI 1.35–1.67, p < 0.01). We observe statistically significant differences in ED revisits for patients receiving hospital-based substance-use support at Health Sciences North. Hospital-based substance-use supports could be applied to other hospitals to reduce 30-day revisits.
本研究比较了在加拿大安大略省萨德伯里市健康科学园(Health Sciences North)接受医院药物使用支持的患者与未接受专门成瘾服务的患者在急诊科(ED)的复诊情况。该研究是一项回顾性观察研究,使用的是2018年1月1日至2022年8月31日期间在Health Sciences North医院就诊的所有药物使用障碍(SUD)患者的管理数据,其ICD-10代码来自出院摘要数据库(DAD)和国家非住院医疗数据库(NACRS)。研究对象包括两种干预措施:成瘾医学咨询服务(AMCS 组)和成瘾医学专科病房(AMU 组)。成瘾医学咨询服务是为急诊室和住院患者提供的咨询服务。AMU 是一个专门的住院医疗单位,旨在为患者提供成瘾支持,以稳定患者病情,其运作理念是减少伤害。主要结果是在急诊室或医院就诊后 30 天内所有原因导致的急诊室复诊。次要结果是在研究期间观察到的所有急诊室复诊情况。Kaplan-Meier 曲线用于测量各暴露组 30 天内再次就诊的比例。使用随机效应逻辑回归模型和 Cox 比例危险模型分别计算了患病率和危险比。研究共纳入5367名患者,其中2018年至2022年期间ED指数就诊10871次,重访2127次。45%(2340/5367)的患者未入院治疗。干预组患者 30 天内再次就诊的可能性较低:急诊室的成瘾医学咨询服务(AMCS)大大降低了复诊几率(OR 0.53,95% CI 0.39-0.71,p < 0.01)和首次复诊几率(OR 0.42,95% CI 0.33-0.53,p < 0.01)。AMU组的复诊几率较低(OR 0.80,95% CI 0.66-0.98,P = 0.03)。年龄每增加一岁,复诊几率略有下降(OR 0.99,95% CI 0.98-1.00,p = 0.01),男性比女性的风险更高(OR 1.50,95% CI 1.35-1.67,p < 0.01)。我们观察到,在北健康科学院接受医院药物滥用支持的患者在急诊室复诊率方面存在明显的统计学差异。医院药物滥用支持可应用于其他医院,以减少 30 天再就诊率。
{"title":"Association of hospital-based substance use supports on emergency department revisits: a retrospective cohort study in Sudbury, Canada from 2018 to 2022","authors":"Mark Tatangelo, Russell Landry, Denis Beaulieu, Catherine Watson, Shannon Knowlan, Alex Anawati, Adele Bodson, Natalie Aubin, David C. Marsh, Tara Leary, Kristen A. Morin","doi":"10.1186/s12954-024-00985-0","DOIUrl":"https://doi.org/10.1186/s12954-024-00985-0","url":null,"abstract":"This study compares emergency department (ED) revisits for patients receiving hospital-based substance-use support compared to those who did not receive specialized addiction services at Health Sciences North in Sudbury, Ontario, Canada. The study is a retrospective observational study using administrative data from all patients presenting with substance use disorder (SUD) at Health Sciences North from January 1, 2018, and August 31, 2022 with ICD-10 codes from the Discharge Abstract Database (DAD) and the National Ambulatory Care Database (NACRS). There were two interventions under study: addiction medicine consult services (AMCS group), and specialized addiction medicine unit (AMU group). The AMCS is a consult service offered for patients in the ED and those who are admitted to the hospital. The AMU is a specialized inpatient medical unit designed to offer addiction support to stabilize patients that operates under a harm-reduction philosophy. The primary outcome was all cause ED revisit within 30 days of the index ED or hospital visit. The secondary outcome was all observed ED revisits in the study period. Kaplan–Meier curves were used to measure the proportion of 30-day revisits by exposure group. Odds ratios and Hazard Ratios were calculated using logistic regression models with random effects and Cox-proportional hazard model respectively. A total of 5,367 patients with 10,871 ED index visits, and 2,127 revisits between 2018 and 2022 are included in the study. 45% (2,340/5,367) of patient were not admitted to hospital. 30-day revisits were less likely among the intervention group: Addiction Medicine Consult Services (AMCS) in the ED significantly reduced the odds of revisits (OR 0.53, 95% CI 0.39–0.71, p < 0.01) and first revisits (OR 0.42, 95% CI 0.33–0.53, p < 0.01). The AMU group was associated with lower revisits odds (OR 0.80, 95% CI 0.66–0.98, p = 0.03). For every additional year of age, the odds of revisits slightly decreased (OR 0.99, 95% CI 0.98–1.00, p = 0.01) and males were found to have an increased risk compared to females (OR 1.50, 95% CI 1.35–1.67, p < 0.01). We observe statistically significant differences in ED revisits for patients receiving hospital-based substance-use support at Health Sciences North. Hospital-based substance-use supports could be applied to other hospitals to reduce 30-day revisits.","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140316216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Harm Reduction Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1